Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity

The following table summarizes information about the Company’s stock options outstanding at March 31, 2017, and activity during the three month period then ended:

					Weighted-
					Average
					Remaining
	Stock		Weighted- Average		Contractual Life		Aggregat Ientrinsic
	Awards		Exercise Price		(Years)		Value
Balance as of December 31, 2016		2,477	$	6.50
Options granted		56	$	3.47
Options exercised		(8)	$	3.05
Options forfeited		(40)	$	8.97
Options cancelled		(19)	$	7.63
Balance as of March 31, 2017		2,466	$	6.39		7.31	$	801
Vested and expected to vest at March 31, 2017		2,466				7.31	$	801
Exercisable as of March 31, 2017		1,352				6.06	$	723

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions

The per-share fair value of each stock option was determined on the date of grant using the Black-Scholes option pricing model using the following assumptions:

	Three months ended March 31,
	2017	2016

Dividend yield	—	—
Risk-free interest rate	2.05% - 2.40%	1.24% - 1.78%
Expected term (in years)	6-10	5-10
Volatility	80% - 82%	77%

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Total stock-based compensation expense related to options granted to employees and non-employees was included in the condensed consolidated statements of operations and comprehensive loss as follows:

	Three months ended March 31,
	2017		2016
Sales and marketing	$	20	$	232
Research and development		101		231
General and administrative		273		1,111
	$	394	$	1,574